BANK VONTOBEL/CALL/BIOGEN IDEC/250/0.01/21.06.24 | Delayed Deutsche Boerse AG 09:31:27 14/06/2024 BST | ||
| 0.002 EUR | 0.00% |
|
| Current month | -80.00% | ||
| 1 month | -84.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.002 | 0.00% |
| 13/06/24 | 0.002 | +100.00% |
| 12/06/24 | 0.001 | -50.00% |
| 11/06/24 | 0.002 | 0.00% |
| 10/06/24 | 0.002 | -33.33% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 09:31 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM2M59 |
| ISIN | DE000VM2M597 |
| Date issued | 18/09/2023 |
| Strike | 250 $ |
| Maturity | 21/06/2024 (8 Days) |
| Parity | 100 : 1 |
| Emission price | 0.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.46 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.018 € |
| Spread % | 90.00% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
233.8
USD
Average target price
284.6
USD
Spread / Average Target
+21.73%
- Stock Market
- Warrants
- Warrant
